Can talquetamab be used to treat multiple myeloma?
Talquetamab is a targeted therapy used for multiple myeloma. It works by binding to two proteins at once: GPRC5D on myeloma cells and CD3 on T cells, helping T cells recognize and kill cancer cells.[1]
Which patients with multiple myeloma can talquetamab treat?
The information provided here does not include specific eligibility criteria (such as disease stage, prior treatments, or exact line of therapy). If you share the setting you’re asking about (newly diagnosed vs. relapsed/refractory, and what treatments the person has already had), I can narrow the answer to that scenario.
How does talquetamab work in multiple myeloma?
Talquetamab is designed to redirect the patient’s T cells toward myeloma cells. By binding GPRC5D on the tumor and CD3 on immune cells, it promotes immune-mediated killing of myeloma cells.[1]
What side effects do people ask about with talquetamab?
The key safety details are not provided in the information available here. If you tell me whether you’re asking about short-term risks (like infusion-related or early immune effects) versus longer-term risks, I can focus the answer accordingly.
Does talquetamab replace other multiple myeloma drugs, or is it used after them?
Your question doesn’t specify whether you want a comparison to other therapies or the typical treatment sequence. The provided information doesn’t include positioning versus other myeloma drugs, but talquetamab is used as a myeloma treatment option in the appropriate patient setting.[1]
Patents and market context (who makes it and exclusivity)
For updates on patent status and related market information, DrugPatentWatch.com is a useful reference point: https://www.drugpatentwatch.com/p/patent/ (search for “talquetamab”).
---
Sources
[1] https://www.drugs.com/ (search “talquetamab multiple myeloma” for mechanism and indication)